Request a copy

Full Text

• BRAUN J, KALDEN JR: Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009; 27: S164-7.
• VAN DER HEIJDE D, KLARESKOG L, RODRÍGUEZ-VALVERDE V ehyt al.: Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006; 54: 1063-74.
• VAN DER HEIJDE D, KLARESKOG L, LANDEWÉ R et al.: Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 3928-39.
• BATHON JM, MARTIN RW, FLEISCHMANN RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
• WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
• WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9.
• MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
• LIPSKY PE, VAN DER HEIJDE DM, ST CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. AntiTumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-602.
• BREEDVELD FC, WEISMAN MH, KAVANAUGH AF et al.: The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37.
• MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al.: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Int Med 1999; 130: 478-86.
• GENOVESE MC, BATHON JM, MARTIN RW et al.: Etanercept versus methotrexate in patients with early rheumatoid arthritis: twoyear radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443-50.
• KLARESKOG L, VAN DER HEUDE D, DE JAGER JP et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis. Lancet 2004; 363: 675-81.
• MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. New Engl J Med 1997; 337: 141-7.
• KLARESKOG L, GAUBITZ M, RODRÍGUEZ-VALVERDE V, MALAISE M, DOUGADOS M, WAJDULA J: A long-term, open-label trial of the safety and efficacy of Etanercept (ENBREL®) in patients with rheumatoid arthritis not treated with other DMARDs (3-year interim report). Ann Rheum Dis 2006; 65: 1578-84.
• Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973-1999 [11 Registries, 1992-1999]) National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2002, based on the November 2001 submission. http://www.seer.cancer.gov.
• KOCHANEK KD, SMITH BL, ANDERSON RN. Deaths: preliminary data for 1999. Natl Vital Stat Rep 2001; 49: 1-48.
• BENSON CA, KAPLAN JE, MASUR H, PAU A, HOLMES KK: Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep 2004; 53: 1-112.
• MARTIN MOLA E, SIEPER J, LEIRISALO-REPO M et al.: Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010; 28: 238-45.
• BONGARTZ T, SUTTON AJ, SWEETING MJ, BUCHAN I, MATTESON EL, MONTORI V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85.
• RIJNEVELD AW, FLORQUIN S, BRANGER J, SPEELMAN P, VAN DEVENTER SJ, VAN DER POLL T: TNF-alpha compensates for the impaired host defense of IL-1 type I receptor-deficient mice during pneumococcal pneumonia. J Immunol 2001; 167: 5240-6.
• DORAN MF, CROWSON CS, POND GR, O'FALLON WM, GABRIEL SE: Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 2287-93.
• SMITTEN AL, CHOI HK, HOCHBERG MC et al.: The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 2008; 35: 387-93.
• MORELAND LW, WEINBLATT ME, KEYSTONE EC et al.: Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 2006; 33: 854-61.
• DIXON WG, WATSON K, LUNT M, HYRICH KL, SILMAN AJ, SYMMONS DP: Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-76.
• LISTING J, STRANGFELD A, KARY S et al.: Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-12.
• ASKLING J, FORED CM, BRANDT L et al.: Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007; 66: 1339-44.
• WALLIS RS: Reconsidering adjuvant immunotherapy for tuberculosis. Clin Infect Dis 2005; 41: 201-8.
• FURST DE, WALLIS R, BRODER M, BEENHOUWER DO: Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006; 36: 159-67.
• KEYSTONE EC: Safety of biologic therapies - an update. J Rheumatol Suppl 2005; 74: 8-12.
• WALLIS RS: Anti-tuberculosis treatment and infliximab. Respir Med 2005; 99: 1620-2.
• SCALLON B, CAI A, SOLOWSKI N et al.: Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301: 418-26.
• SALIU OY, SOFER C, STEIN DS, SCHWANDER SK, WALLIS RS: Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006; 194: 486-92.
• WOLFE F, MICHAUD K: Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50: 1740-51.
• DEVOOGDT N, REVETS H, KINDTA, LIU YQ, DE BAETSELIER P, GHASSABEH GH: The tumor-promoting effect of TNF-alpha involves the induction of secretory leukocyte protease inhibitor. J Immunol 2006; 177: 8046-52.
• DZIADZIO M, SMITH R: Meta-analysis is no substitute for a comprehensive national registry. Clin Rheumatol 2007; 26: 1134-5.
• ASKLING J, FORED CM, BRANDT L et al.: Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1421-6.
• ASKLING J, FORED CM, GEBOREK P et al.: Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006; 65: 707-12.
• BONGARTZ T, WARREN FC, MINES D, MATTESON EL, ABRAMS KR, SUTTON AJ: Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 2009; 68: 1177-83.
• NAM JL, WINTHROP KL, VAN VOLLENHOVEN RF et al.: Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010; 69: 976-86.
• WOLFE F, MICHAUD K: Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56: 2886-95.
• WOLFE F, MICHAUD K: The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007; 56: 1433-9.
• GEBOREK P, BLADSTROM A, TURESSON C et al.: Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005; 64: 699-703.
• ASKLING J, VAN VOLLENHOVEN RF, GRANATH F et al.: Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009; 60: 3180-9.
• ASKLING J, BAECKLUND E, GRANATH F et al.: Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009; 68: 648-53.
• NICOLA PJ, CROWSON CS, MARADIT-KREMERS H et al.: Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum 2006; 54: 60-7.
• SOKKA T, ABELSON B, PINCUS T: Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008; 26: S35-61.
• SIHVONEN S, KORPELA M, LAIPPALA P, MUSTONEN J, PASTERNACK A: Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol 2004; 33: 221-7.
• DORAN MF, POND GR, CROWSON CS, OFALLON WM, GABRIEL SE: Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 2002; 46: 625-31.
• CHEHATA JC, HASSELL AB, CLARKE SA et al.: Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity. Rheumatology (Oxford) 2001; 40: 447-52.
• WOLFE F, MITCHELL DM, SIBLEY JT et al.: The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481-94.
• CARMONA L, DESCALZO MA, PEREZ-PAMPIN E et al.: All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007; 66: 880-5.
• BOOK C, SAXNE T, JACOBSSON LT: Prediction of mortality in rheumatoid arthritis based on disease activity markers. J Rheumatol 2005; 32: 430-4.
• BARTELDS GM, WOLBINK GJ, STAPEL S et al.: High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. Ann Rheum Dis 2006; 65: 1249-50.
• RADSTAKE TR, SVENSON M, EIJSBOUTS AM et al.: Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1739-45.